Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Solagran has reported that the Russian regulatory authorities were expected to release its new prescription pharmaceutical Ropren for sale in the Russian market within 30 to 45 days.
Subscribe to our email newsletter
Solagran’s manufacturing partner Galenopharm is now free to commence production of Ropren for sale throughout Russia. Solagran is hopeful that initial production volumes will be sufficient to meet the needs of the main population centres of Moscow and St Petersburg.
Solagran will now turn its attention to ensuring that it is in a position to respond effectively to the significant world wide interest in this product. A plant containing the world’s first commercial polyprenols production facility is due to be opened shortly by the Governor of the Tomsk region. When operated at full capacity, this facility will generate sufficient polyprenols (Bioeffective R) to produce 50-60,000 courses of Ropren per annum.
These two events constitute a really major milestone for the company and mark the beginning of Solagran’s transition from a research-focused biotechnology company into an important player in the international natural pharmaceuticals market.